UPB
Upstream Bio, Inc.
NASDAQ · USHealthcareBiotechnology
$6.98-0.43%
Price as of Jul 20, 2026
UPB financials
Upstream Bio, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $2.9M | $2.4M | $2.4M | $1.2M |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $2.9M | $2.4M | $2.4M | $1.2M |
| Operating expenses | $163.2M | $80.1M | $42.5M | $25.1M |
| Operating income | -$160.4M | -$77.8M | -$40.1M | -$23.9M |
| Net income | -$143.4M | -$62.8M | -$20.5M | -$23.9M |
| EBITDA | -$143.3M | -$62.7M | -$20.5M | -$23.9M |
| Basic EPS | $-2.66 | $-1.49 | $-1.05 | $-0.66 |
| Diluted EPS | $-2.66 | $-1.49 | $-1.05 | $-0.66 |
| Balance sheet | ||||
| Cash & equivalents | $101.6M | $325.9M | $25.8M | $17.1M |
| Total assets | $353.8M | $481.7M | $117.2M | $18.5M |
| Total liabilities | $14.0M | $11.9M | $240.3M | $124.6M |
| Stockholders’ equity | $339.8M | $469.9M | -$123.1M | -$106.2M |
| Total debt | $1.3M | $1.8M | $45.0K | $94.0K |
| Net debt | -$100.3M | -$324.1M | -$25.8M | -$17.0M |
| Cash flow | ||||
| Operating cash flow | -$133.3M | -$59.2M | -$37.9M | -$19.0M |
| Capital expenditure | -$165.0K | -$511.0K | -$144.0K | -$82.0K |
| Free cash flow | -$133.3M | -$59.7M | -$38.1M | -$19.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |